Second Department of Breast Tumor, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, China; National Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Ministry of Education, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, China.
National Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Ministry of Education, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, China; Department of Breast Cancer Pathology and Research Laboratory, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, China.
Pathol Res Pract. 2020 Jun;216(6):152948. doi: 10.1016/j.prp.2020.152948. Epub 2020 Apr 5.
Primary signet ring cell carcinoma (SRCC) of the breast is a rare entity, and only a few case reports of the pure SRCC cases could be found in English literatures. We summarized the clinicopathological characteristics of a relatively large cohort of pure breast SRCCs for the first time.
We reviewed the medical records of 23 cases of pure breast SRCC with a median follow-up time of 70 months.
Three patients had bilateral primary breast cancer (BC) and two of them had bilateral pure SRCCs. 30 % of patients had the malignant tumor family history including two bilateral BC patients. Malignant calcification was observed in 35.3 % of mammography images. Multifocal lesions were microscopically found in 26.1 % of cases. 63.6 % of the cases had lymph node metastasis, 45.5 % were classified as Stage III, 69.6 % had high value of Ki-67 index, and 34.8 % were triple negative subtype. 19.0 % of patients had local recurrence, and 52.6 % had distant metastasis. Four in five patients with positive tumor family history and follow-up data had relapse of SRCC. The 5-year overall survival rate was 73.7 %, the 5-year relapse-free survival rate was 54.3 %, and the 5-year breast cancer specific survival rate was 78.3 %.
Pure SRCC of the breast showed an aggressive behavior. Neoadjuvant chemotherapy could be considered, breast-conserving surgery should be prudently chosen, and axillary lymph node dissection may be necessary. The high rate of positive tumor family histories and high bilateral incidence, which showed an adverse effect on prognosis, indicate the unique genetic burden of SRCC.
原发性印戒细胞乳腺癌(SRCC)是一种罕见的疾病,在英文文献中仅能找到少数纯 SRCC 病例的报道。我们首次总结了一组相对较大的纯乳腺 SRCC 病例的临床病理特征。
我们回顾性分析了 23 例纯乳腺 SRCC 患者的病历资料,中位随访时间为 70 个月。
3 例患者为双侧原发性乳腺癌(BC),其中 2 例为双侧纯 SRCC。30%的患者有恶性肿瘤家族史,包括 2 例双侧 BC 患者。35.3%的乳腺 X 线照片可见恶性钙化。26.1%的病例镜下可见多发病灶。63.6%的病例有淋巴结转移,45.5%的病例分期为 III 期,Ki-67 指数高值者占 69.6%,三阴性亚型占 34.8%。19.0%的患者有局部复发,52.6%的患者有远处转移。肿瘤家族史阳性且有随访数据的患者中,有 4/5 例发生了 SRCC 复发。5 年总生存率为 73.7%,5 年无复发生存率为 54.3%,5 年乳腺癌特异性生存率为 78.3%。
纯乳腺 SRCC 具有侵袭性行为。可考虑新辅助化疗,应慎重选择保乳手术,必要时行腋窝淋巴结清扫。较高的肿瘤家族史阳性率和双侧较高的发生率对预后产生不利影响,提示 SRCC 存在独特的遗传负担。